169 related articles for article (PubMed ID: 37953243)
1. Twenty-five years with companion diagnostics.
Jørgensen JT
Chin Clin Oncol; 2023 Dec; 12(6):65. PubMed ID: 37953243
[TBL] [Abstract][Full Text] [Related]
2. Oncology drug-companion diagnostic combinations.
Jørgensen JT
Cancer Treat Res Commun; 2021; 29():100492. PubMed ID: 34844911
[TBL] [Abstract][Full Text] [Related]
3. Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs.
Jørgensen JT
JCO Precis Oncol; 2022 Jun; 6():e2200100. PubMed ID: 35709402
[TBL] [Abstract][Full Text] [Related]
4. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
5. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
[TBL] [Abstract][Full Text] [Related]
6. The current landscape of the FDA approved companion diagnostics.
Jørgensen JT
Transl Oncol; 2021 Jun; 14(6):101063. PubMed ID: 33714919
[TBL] [Abstract][Full Text] [Related]
7. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives.
Jørgensen JT
Trends Cancer; 2016 Dec; 2(12):706-712. PubMed ID: 28741518
[TBL] [Abstract][Full Text] [Related]
8. Companion Diagnostics and Molecular Imaging.
Puranik AD; Kulkarni HR; Baum RP
Cancer J; 2015; 21(3):213-7. PubMed ID: 26049701
[TBL] [Abstract][Full Text] [Related]
9. A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer.
Jørgensen JT; Winther H; Askaa J; Andresen L; Olsen D; Mollerup J
Front Oncol; 2021; 11():676939. PubMed ID: 34367962
[TBL] [Abstract][Full Text] [Related]
10. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
11. Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Hersom M; Jørgensen JT
Ther Drug Monit; 2018 Feb; 40(1):9-16. PubMed ID: 29084031
[TBL] [Abstract][Full Text] [Related]
12. HER2--a discussion of testing approaches in the USA.
Thor A
Ann Oncol; 2001; 12 Suppl 1():S101-7. PubMed ID: 11521714
[TBL] [Abstract][Full Text] [Related]
13. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
[TBL] [Abstract][Full Text] [Related]
14. The Regulation of Companion Diagnostics: A Global Perspective.
Ansari M
Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516
[TBL] [Abstract][Full Text] [Related]
15. Companion and complementary diagnostics for infectious diseases.
Dailey PJ; Elbeik T; Holodniy M
Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
[TBL] [Abstract][Full Text] [Related]
16. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
Olsen D; Jørgensen JT
Front Oncol; 2014; 4():105. PubMed ID: 24904822
[TBL] [Abstract][Full Text] [Related]
17. [Companion diagnostics with FISH assay (HER2, ALK)].
Hiraoka M
Rinsho Byori; 2014 Apr; 62(4):390-8. PubMed ID: 25022069
[TBL] [Abstract][Full Text] [Related]
18. Changes in Companion Diagnostic Labelling: Implementation of FDA's April 2020 Guidance for Industry for In Vitro CDx Labeling for Specific Oncology Therapeutic Groups.
Cooper L; Chen J
Ther Innov Regul Sci; 2022 Sep; 56(5):689-697. PubMed ID: 35689144
[TBL] [Abstract][Full Text] [Related]
19. Protein array-based companion diagnostics in precision medicine.
Poulsen TBG; Karamehmedovic A; Aboo C; Jørgensen MM; Yu X; Fang X; Blackburn JM; Nielsen CH; Kragstrup TW; Stensballe A
Expert Rev Mol Diagn; 2020 Dec; 20(12):1183-1198. PubMed ID: 33315478
[TBL] [Abstract][Full Text] [Related]
20. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
